Publikationen in Zusammenarbeit mit Forschern von Università di Perugia (20)

2022

  1. Guiding the global evolution of cytogenetic testing for hematologic malignancies

    Blood, Vol. 139, Núm. 15, pp. 2273-2284

  2. Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study

    The Lancet Haematology, Vol. 9, Núm. 2, pp. e98-e110

  3. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

    Blood, Vol. 140, Núm. 11, pp. 1229-1253

2021

  1. Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 21, Núm. 11, pp. 785-798

2020

  1. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial

    The Lancet, Vol. 396, Núm. 10262, pp. 1563-1573

2019

  1. Systemic manifestations of primary Sjögren's syndrome out of the ESSDAI classification: Prevalence and clinical relevance in a large international, multi-ethnic cohort of patients

    Clinical and Experimental Rheumatology, Vol. 37, pp. S97-S106

  2. The Big Data Sjögren consortium: A project for a new data science era

    Clinical and Experimental Rheumatology, Vol. 37, pp. S19-S23

2018

  1. How immunological profile drives clinical phenotype of primary Sjögren's syndrome at diagnosis: Analysis of 10,500 patients (Sjögren Big Data Project)

    Clinical and Experimental Rheumatology, Vol. 36, pp. S102-S111

  2. Maintenance Treatment and Survival in Patients with Myeloma: A Systematic Review and Network Meta-analysis

    JAMA Oncology, Vol. 4, Núm. 10, pp. 1389-1397

2017

  1. Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma

    British Journal of Haematology, Vol. 178, Núm. 4, pp. 571-582

2014

  1. Research update for articles published in EJCI in 2012

    European Journal of Clinical Investigation, Vol. 44, Núm. 10, pp. 1010-1023

2013

  1. Age and organ damage correlate with poor survival in myeloma patients: Meta-analysis of 1435 individual patient data from 4 randomized trials

    Haematologica, Vol. 98, Núm. 6, pp. 980-987

2006

  1. Characterization of a recurrent translocation t(2;3)(p15-22;q26) occurring in acute myeloid leukaemia

    Leukemia, Vol. 20, Núm. 1, pp. 48-54

1997

  1. del(7q) in chronic B-cell lymphoid malignancies

    Cancer Genetics and Cytogenetics, Vol. 93, Núm. 2, pp. 147-151

1996

  1. BCL3 rearrangement and t(14;19)(q32;q13) in lymphoproliferative disorders

    Genes Chromosomes and Cancer, Vol. 15, Núm. 1, pp. 38-47

  2. Deletions of the long arm of chromosome 7 in myeloid disorders: Loss of band 7q32 implies worst prognosis

    British Journal of Haematology, Vol. 92, Núm. 3, pp. 574-581

1995

  1. Characterization by chromosome painting of balanced and unbalanced x chromosome translocations in myelodysplastic syndromes

    Cancer Genetics and Cytogenetics, Vol. 82, Núm. 1, pp. 17-22

  2. Cytogenetic analysis of B cell chronic lymphoid leukemias classified according to morphologic and immunophenotypic (FAB) criteria

    Leukemia, Vol. 9, Núm. 12, pp. 2140-2146

  3. Fluorescence in situ hybridization identifies new chromosomal changes involving 3q27 in non‐Hodgkin's lymphomas with BCL6/LAZ3 rearrangement

    Genes, Chromosomes and Cancer, Vol. 14, Núm. 1, pp. 1-7

  4. Translocation (11;15)(q23;q14) in three patients with acute non-lymphoblastic leukemia (ANLL): Clinical, cytogenetic and molecular studies

    Leukemia, Vol. 9, Núm. 7, pp. 1162-1166